Personalized Prediction Strategy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

442 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-08-01

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a 3-year longitudinal study designed to establish a personalized prediction and prevention system for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Data will be prospectively collected from patients with chronic obstructive pulmonary disease (COPD) and healthy control participants, including clinical characteristics, pathophysiological parameters, etiological factors, and immunological information. These data will be analyzed using data mining approaches combined with Internet-based technologies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Cohort of Patients With Chronic Pulmonary Disease

NCT04050943

Obstructive Pulmonary Disease

UNKNOWN

Risk Prediction Model for Exacerbating Phenotype in Patients With Chronic Obstructive Pulmonary Disease

NCT06198309

Chronic Obstructive Pulmonary Disease Severe

RECRUITING

A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Early COPD Outcomes in Chinese Population

NCT06724848

COPD

RECRUITING

Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease

NCT03450603

Chronic Obstructive Pulmonary Disease

RECRUITING

Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study

NCT02657525

Chronic Obstructive Pulmonary Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COPD subjects

Subjects with GOLD stage I-IV COPD

No interventions assigned to this group

Healthy control subjects

Ages 40 to 90, with no history of lung disease and no history of acute illness or medication use within the past month.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients was diagnosed as COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines older than 40 years old.

* A signed and dated written informed consent is obtained prior to participation.
* Able to comply with the requirements of the protocol and be available for study visits over 3 years.

Exclusion Criteria

* A COPD subject will not be eligible for inclusion in this study if any of the following criteria apply:

* Known respiratory disorders, or disorders identified at screening/visit 1 (including identification on the first CT scan), other than COPD (e.g.: lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis)
* Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid arthritis and Lupus)
* Known to be severely alpha-1-antitrypsin deficient
* Has experienced a moderate or severe exacerbation (requiring oral corticosteroid, antibiotics or hospitalisation) within the last 4 weeks
* Having undergone lung surgery (e.g. lung reduction, lung transplant)
* Have cancer or have had cancer in the 5 years prior to study entry
* Having received a blood transfusion in the 4 weeks prior to study start
* Inability to walk
* Taking part in a blinded drug study
* Having therapy with systemic corticosteroids at inclusion.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No